GentiBio and BMS partner to develop inflammatory bowel disease therapies
BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.

BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.
The proceeds will be utilised to advance the pipeline of Disc to clinical trials and provide runway into 2025.
Metrics’ Greenville facility will be integrated into oral development and manufacturing network of Catalent.
Cerevance is entitled to receive development and commercial milestone payments of nearly $1.1bn.
With the acquisition, Albumedix will become part of the Bioprocess Solutions Division of Sartorius.
GBT takeover complements and boosts Pfizer’s expertise in rare haematology.
The board of directors of Amgen and ChemoCentryx has granted unanimous approval for the acquisition.
Gilead will gain access to the discovery platform and complete line of the immune inhibitory receptor agonists of MiroBio.
Thank you for subscribing to Pharmaceutical Technology